Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must meet the following criteria for study entry:
Histologically confirmed NSCLC
Availability of a tumor specimen
Recurrent or progressive disease following at least one chemo containing regimen for Stage IIIB/IV disease
Measurable disease in accordance with Response Evaluation Criteria in Solid Tumors (RECIST)
At least one measurable lesion on a pre-treatment 18-fluorodeoxyglcose-positron emission tomography (FDG-PET) scan that is also a target lesion on computed tomography (CT) according to RECIST
You may not be if
More than two prior treatments for Stage IIIB/IV
More than 30 days of exposure to an investigational or marketed agent that can act by EGFR inhibition, or a known epidermal growth factor receptor (EGFR)-related toxicity resulting in dose modifications
Chemotherapy, biologic therapy, radiotherapy or investigational drug within 28 days prior to randomization
Untreated and/or active (progressing or requiring anticonvulsants or corticosteroids for symptomatic control) central nervous system (CNS) metastasis
History of serious systemic disease within the past 6 months prior to randomization
Uncontrolled diabetes
Major surgical procedure or significant traumatic injury within 28 days prior to randomization
Anticipation of need for a major surgical procedure during the course of the study
Local palliative radiotherapy within 7 days prior to randomization or persistent adverse effects from radiotherapy that have not been resolved to Grade II or less prior to randomization
Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy
